70results about "Liver cancer vaccine" patented technology

The invention provides a chimeric antigen receptor (CAR) targeting NKG2D. Amino acid sequences of the CAR targeting NKG2D comprises the amino acid sequences of a single-chain antibody targeting NKG2D,an extracellular hinge region, a transmembrane region and an intracellular signal region which are sequentially connected from an amino terminal to a carboxyl terminal, respectively. The single-chainantibody targeting NKG2D comprises the amino acid sequences shown in SEQ ID NO: 1. The invention also provides a chimeric antigen receptor T-cell (CAR-T) targeting NKG2D and a preparation method thereof, as well as application of the CAR targeting NKG2D and the CAR-T targeting NKG2D in the prevention, diagnosis and treatment of liver cancer, cervical cancer, pancreatic cancer and other malignanttumors.

The invention discloses a double-chimeric antigen receptor, a T cell and a construction method and an application thereof, which belong to the field of cellular immunotherapy of tumors. The inventionspecifically relates to a specific structure and a construction method of the double chimeric antigen receptor T cell (dCAR-T cell), and preliminarily discusses the in-vivo and in-vitro activity of the dCAR-T cell. The selected tumor-associated antigens are mesothelin and carcino-embryonic antigens, and researches show that the two tumor antigens can be simultaneously expressed on the surface of asolid tumor, such as pancreatic cancer. The invention discloses an antigen receptor. The in-vitro and in-vivo tests prove that the constructed dCAR-T cell can be permanently and effectively activatedonly under the condition that two antigens are simultaneously recognized, and has efficient anti-tumor activity, so that a specific tumor killing function can be exerted, and the application of CAR-Tcell immunotherapy is improved.

The invention relates to chimeric antigen receptor T cell (CAR-T) in the treatment of hepatocellular carcinama (HCC) by targeting hepatitis B virus (HBV) and an application thereof. In order to overcome a potential multiple organ off-target effect in the existing CAR-T treatment of HCC, the inventor, after repeated screening, prepares chimeric antigen receptor T cells targeting HBV surface antigen (HBVsAg). The results show that CAR-T prepared in the invention has a good killing effect on HBV positive HCC cells, and has a significantly higher killing effect than the CAR-T cells targeting GPC3 in current clinical trials and researches, showing a better application prospect.

The invention relates to a new embedded antigen acceptor, and provides an expression vector for expressing the embedded antigen acceptor and a host cell. The invention further provides an applicationof the embedded antigen acceptor to treatment of cancer or preparation of medicines for treating cancer. The embedded antigen acceptor and the medicines, provided by the invention, can effectively treat lung cancer.

The invention discloses a chimeric antigen receptor T lymphocyte and an application thereof to preparation of a product for treating solid tumors. A chimeric antigen receptor in the chimeric antigen receptor T lymphocyte sequentially comprises a human CD8 lead peptide, an anti-Siglec-15 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleavage peptide, a CSF2Ra signal peptide, an EGFRt protein, a self-cleavage peptide and a human CD27. Experiments prove that the chimeric antigen receptor T lymphocyte provided by the invention highly expresses IFN gamma and CD107a, has a strong killing function on Siglec-15 positive tumor cells, and has killing efficiency of more than 80% under the condition thatthe effect-target ratio is 1: 1. A tumor transplantation model experiment shows that the chimeric antigen receptor T lymphocyte also has a strong killing function on Siglec-15 positive tumor cells inan animal body.

The invention provides a preparation method of bispecific antibody NK cells, and cells and application thereof. The method comprises the following steps of: culturing NK cells, constructing a CD16A / HSP70 bispecific antibody lentiviral expression vector, and infecting the NK cells by the CD16A / HSP70 bispecific antibody lentiviral expression vector so as to obtain the bispecific antibody NK cells ofa CD16A / HSP70 antibody. The NK cells prepared by the invention are excellent in cell-specific phenotype and high in purity, wherein CD3-CD56+ achieves 97.13%; CD3-CD56+CD16+ achieves 93%; and the NKcells carrying the CD16A / HSP70 bispecific antibody lentiviral expression vector can effectively eliminate liver cancer cells and inhibit increasing of the tumour volume of the liver cancer.

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises a GPC3 antigen binding structural domain, an ICD1, ICD2 or ICD3 intracellular signal stimulation domain withamino acid sequences of SEQ ID NO.29, 31 and 33 and IL-15-IL-15alpha fusion protein with an amino acid sequence of SEQ ID NO.7. After the chimeric antigen receptor is transferred into immune cells, especially iNKT cells, the cell proliferation speed, the survival time and the tumour killing effect can be effectively improved. The invention further provides a corresponding expression vector, a transduction system, pharmaceutical application, independent ICD1, ICD2 and ICD3 intracellular signal stimulation domains and IL-15-IL-15alpha fusion protein.

The invention discloses an immunoenhancer, an immunotherapy medicine composition, a preparation method of the immunotherapy medicine composition and an application of the immunoenhancer and the immunotherapy medicine composition. The immunoenhancer at least comprises interferon and granular cell-macrophage colony stimulating factors, and the immunotherapy medicine composition at least comprises antigen and the immunoenhancer. The immunoenhancer can remarkably enhance the immunity of a body and improve the antigen presenting efficiency of the body, so that the body can establish effective immune activation and response. Strong antibody and cellular immune protection reaction and pathogen removing capacity can be generated, and the immunoenhancer can be applied to therapy of diseases and tumors caused by microorganisms such as viruses and bacteria.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention discloses a PD-L1 CAR structure, a specific structure of a CAR sequence of the PD-L1 CAR structure is as follows: a CD8 alpha leading peptide-PD-L1 scFv-CD8 alpha transmembrane region, aCD137 intracellular costimulatory domain, a CD247 intracellular activation domain. Tumor targeting and T cell double-activation pathway molecules are integrated into a single PD-L1 chimeric receptorgene, so that the feasibility of treating solid tumors by genetically modified T cells is greatly improved, the preparation cost is reduced, and the product can be applied to treatment of PD-L1 high-expression solid tumors, such as lung cancer, liver cancer, colon cancer and the like.

The invention discloses a synergistic and depletion-resistant chimeric antigen receptor T cell and application thereof in preparation of a medicine for treating tumors. The synergistic and depletion-resistant chimeric antigen receptor T cell comprises an antigen binding structural domain (scFv) and a signal transduction structural domain, wherein the signal transduction structural domain comprises a first transduction structural domain and a second transduction structural domain, and the antigen binding structural domain is connected in series between the first transduction structural domain and the second transduction structural domain; the first conduction structural domain comprises a receptor signal structural domain and / or a costimulatory structural domain; the second conductive domain comprises a transmembrane structural domain DAP12, and the transmembrane structural domain DAP12 is or is not linked to the costimulatory structural domain and / or an elementary signal domain. According to the T cell expressing the chimeric antigen receptor, the chimeric antigen receptor can be more efficiently and stably expressed in the T cell, so that a killing effect on a target cell can be better played, the durability of CAR-T is improved, the expression of a depletion marker is lower, and the memory type T cell is richer.

The present invention belongs to the field of biotechnology and pharmaceuticals. The present inventors found a sequence motif for identifying potent RIG-I agonists. Accordingly, the present invention is directed to a method for producing RIG-I agonists, the RIG-I agonists produced by said methods, and uses of said RIG-I agonists, as defined in the claims.

The invention provides a novel chimeric antigen receptor, an expression vector and a host cell for expressing the chimeric antigen receptor, and application of the chimeric antigen receptor in cancertreatment or preparation of medicines for treating cancers. The chimeric antigen receptor and medicines can be used for treating cancers, such as liver cancer and the like.